ArriVent Q2 net loss widens to $49.89 million; R&D expenses rise to $42.34 million

• ArriVent posted a Q2 net loss of USD 49.89 million, widening from USD 31.4 million a year earlier.
• R&D expense climbed to USD 42.34 million from USD 27.72 million, while G&A rose to USD 10.35 million from USD 5.9 million.
• Operating loss widened to USD 52.69 million from USD 33.62 million; interest and investment income increased to USD 2.8 million from USD 2.22 million.
• Cash and investments totaled USD 373.1 million at June 30, expected to fund operations into 2028.
• Topline Phase 3 FURVENT data for firmonertinib in first-line EGFR exon 20 insertion NSCLC is expected in 2H 2026; first ARR-002 patient dosing is expected in Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608121601PRIMZONEFULLFEED9808825) on August 12, 2026, and is solely responsible for the information contained therein.